Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1-Reference-Cited by-同舟云学术

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1

Published:2016-05-28 Issue:1 Volume:52 Page:94-103
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Iio Etsuko,Shimada Noritomo,Abe Hiroshi,Atsukawa Masanori,Yoshizawa Kai,Takaguchi Koichi,Eguchi Yuichiro,Nomura Hideyuki,Kuramitsu Tomoyuki,Kang Jong-Hon,Matsui Takeshi,Hirashima Noboru,Tsubota Akihito,Kusakabe Atsunori,Hasegawa Izumi,Miyaki Tomokatsu,Shinkai Noboru,Fujiwara Kei,Nojiri Shunsuke,Tanaka Yasuhito

Funder

Research Program on Hepatitis from Japan Agency for Medical Research and development, AMED.

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-016-1225-x.pdf

Reference28 articles.

1. Lavanchy D. The global burden of hepatitis C. Liver Int Off J Int Assoc Study Liver. 2009;29(Suppl 1):74–81.

2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl J Med. 2011;364(25):2405–16.

3. Ogawa E, Furusyo N, Dohmen K, et al. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. J Viral Hepat. 2015;22(12):992–1001.